Navigation Links
Experimental treatment protects monkeys from lethal Ebola virus post-exposure
Date:5/28/2010

Scientists using tiny particles of genetic material to interfere in the replication process of the deadly Ebola virus have successfully prevented monkeys exposed to that virus from dying of hemorrhagic fever. The proof-of-concept study, published in this week's issue of The Lancet, suggests that such protection also should be possible in humans.

"Over the past decade, we have evaluated numerous therapeutic approaches for the treatment of lethal viruses, such as Ebola," said co-author Dr. Lisa E. Hensley of the U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID). "None of them have conferred complete protection to Ebola virus-infected primatesuntil now."

Using particles called small interfering RNAs (siRNAs), the authors targeted a protein (called the L protein) that is essential for Ebola virus replication. RNA inhibitors, as they are commonly called, are based on a natural gene silencing mechanism used by all cells, and RNAi therapeutics rely on a delivery technology to be effective.

Lipid nanoparticles (LNPs) are the most widely used siRNA delivery approaches. In this study, the research team used a proprietary technology called SNALP, or stable nucleic acid-lipid particles, to deliver the therapeutics to disease sites in animal models infected with the Zaire strain of Ebola virus (ZEBOV).

A group of three rhesus macaques was given anti-ZEBOV siRNAs intravenously, 30 minutes after exposure to the virus, and again on days 1, 3, and 5. A second group of four macaques was given the treatment after 30 minutes, and on days 1, 2, 3, 4, 5, and 6, after challenge with ZEBOV.

Two of the three animals in the first group (which received four post-exposure treatments) were protected from lethal ZEBOV infection and survived. All four of the monkeys given seven post-exposure treatments were protected. The treatment regimen in the second study was well tolerated, with minor changes in liver enzymes that might have been related to viral infection.

The study represents the first demonstration of complete protection against a lethal human infectious disease in nonhuman primates using RNAi, according to lead author Dr. Thomas W. Geisbert of the Boston University School of Medicine.

"We believe this work justifies the immediate development of Ebola SNALP as a countermeasure to treat Ebola infected patients, either in outbreaks or accidental laboratory exposures," he said.

Ebola virus causes hemorrhagic fever with case fatality rates as high as 80 percent in humans. The virus, which is infectious by aerosol (although more commonly spread through blood and bodily fluids of infected patients), is of concern both as a global health threat and a potential agent of biological warfare or terrorism.

Currently there are no available vaccines or therapies, so researchers working with Ebola virus must do so in maximum containment (Biosafety Level 4) laboratories. In these specially designed laboratories, investigators wear positive pressure "space suits" and breathe filtered air as they work, and all laboratory waste streams are sterilized.

The SNALP-RNAi therapeutic used in the study was developed by Tekmira Pharmaceuticals Corporation of Vancouver, BC. Previous research showed that these siRNAs completely protected guinea pigs when administered shortly after a lethal dose of ZEBOV was administered. While rodent studies are useful for screening prospective medical countermeasures, they are frequently not useful for prediction of efficacy in the more stringent non-human primate models.

Further studies in monkeys would be necessary to refine dosing, toxicology and other issued before the treatment could be licensed for human use.

"The significance of this report goes beyond the protection against Ebola virus," said COL John P. Skvorak, commander of USAMRIID. "It also represents the potential for this concept to be applied to other viral infections."


'/>"/>

Contact: Caree Vander Linden
caree.vanderlinden@us.army.mil
301-619-2285
US Army Medical Research Institute of Infectious Diseases
Source:Eurekalert

Related biology news :

1. Experimental Biology 2008 meets in San Diego April 5-9
2. Translational research patented first experimental treatment against idiopathic pulmonary fibrosis
3. Experimental Biology and Medicine announces expansion into Asia, opens new office
4. Experimental chemotherapy regimen shows promise in treating advanced lung cancer
5. French scientist wins the Journal of Experimental Biology Outstanding Paper Prize
6. Survival in a Changing World: The Journal of Experimental Biology 2009 symposium
7. 40 minority scientists receive travel fellowships to Experimental Biology 2009 in New Orleans
8. Experimental treatment halts hypoxic-ischemic brain injury in newborns
9. Experimental treatments restore partial vision to blind people
10. Experimental drug shows promise against brain, prostate cancers
11. French scientist wins the Journal of Experimental Biology Outstanding Paper Prize 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/31/2016)... , March 31, 2016  Genomics firm Nabsys has ... CEO, Barrett Bready , M.D., who returned to ... the original technical leadership team, including Chief Technology Officer, ... Product Development, Steve Nurnberg and Vice President of Software ... the company. Dr. Bready served as CEO ...
(Date:3/21/2016)... Massachusetts , March 22, 2016 ... facial recognition with passcodes for superior security   ... ), a leading provider of secure digital communications services, ... their biometric technology and offer enterprise customers, particularly those ... secure facial recognition and voice authentication within a mobile ...
(Date:3/14/2016)... March 14, 2016 NXTD ) ("NXT-ID" ... commerce market, announces the airing of a new series of ... week of March 21 st .  The commercials will air ... popular Squawk on the Street show. --> NXTD ... growing mobile commerce market, announces the airing of a new ...
Breaking Biology News(10 mins):
(Date:5/23/2016)... ... ... for blood donations in South Texas and across the nation is growing. , But according ... donations are on the decline. In fact, donations across the country are at their lowest ... in the last four years alone. , There is no substitute for blood. , “We ...
(Date:5/23/2016)... ... May 23, 2016 , ... RoviSys, a leading independent ... Aurora, Ohio, has broken ground on a new building in Holly Springs, NC. ... this new location solidifies a commitment to business in the region. The new ...
(Date:5/20/2016)... ... , ... Korean researchers say Manumycin A triggers apoptosis, or natural cell death, ... the disease. Surviving Mesothelioma has just posted an article on the new study. ... their mesothelioma study on the fact the Manumycin A, a derivative of Streptomyces parvulus, ...
(Date:5/19/2016)... ... 19, 2016 , ... KCAS Bioanalytical and Biomarker Services, a ... Large Molecule & Biomarker Bioanalysis. , Dr. Siddiqui has more than 15 years ... preclinical and clinical safety programs. “We’ve seen significant demand for, and we are ...
Breaking Biology Technology: